HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 43, 33336-33345, October 27, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/43/33336    most recent M006145200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brewer, G. Search for Related Content PubMed PubMed Citation Articles by Brewer, G. Social Bookmarking                      What's this?

Regulation of c-myc mRNA Decay in Vitro by a Phorbol Ester-inducible, Ribosome-associated Component in Differentiating Megakaryoblasts^*

Gary Brewer

From the Department of Molecular Genetics and Microbiology, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854

Received for publication, July 12, 2000, and in revised form, August 6, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The K562 leukemia cell line is bipotential for erythroid and megakaryoblastic differentiation. The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) activates a genetic program of gene expression in these cells leading to their differentiation into megakaryoblasts, a platelet precursor. Thus, K562 cells offer a means to examine early changes in gene expression necessary for megakaryoblastic commitment and differentiation. An essential requirement for differentiation of many hematopoietic cell types is the down-regulation of c-myc expression, because its constitutive expression blocks differentiation. TPA-induced differentiation of K562 cells causes rapid down-regulation of c-myc expression, due in part to an mRNA decay rate that is 4-fold faster compared with dividing cells. A cell-free mRNA decay system reconstitutes TPA-induced destabilization of c-myc mRNA, but it requires at least two components for reconstitution. One component fractionates to the post-ribosomal supernatant from either untreated or treated cells. This component is sensitive to cycloheximide and micrococcal nuclease. The other component is polysome-associated and is induced or activated by TPA. Although in dividing cells c-myc mRNA decays via a sequential pathway involving removal of the poly(A) tract followed by degradation of the mRNA body, TPA activates a deadenylation-independent pathway. The cell-free mRNA decay system reconstitutes this alternate decay pathway as well.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Specific and timely changes in gene expression are required for cellular differentiation and proper embryonic development (reviewed in Ref. 1). Although gene expression can be regulated at many levels, the rates at which individual mRNAs decay is a major factor contributing to steady-state mRNA levels (reviewed in Ref. 2). The degradation rates of individual mRNAs can vary by an order of magnitude or more. Additionally, these rates can vary as a consequence of differentiation or a particular stage of the cell cycle. Such variations apparently comprise part of the normal pleiotropic response to cellular proliferation and differentiation signals and usually involve only a subset of mRNAs.

One such developmental system for studies of gene expression is the human cell line K562 (3, 4). K562 cells are bipotential for erythroid and megakaryoblastic development. Treatment of K562 cells with the protein kinase C activator 12-O-tetradecanoylphorbol-13-acetate (TPA¹) leads to loss of erythroid properties and maturation into megakaryoblasts, the precursor to platelets (reviewed in Ref. 5). The maturation processes resemble those observed during normal platelet development and include the following: inhibition of cellular replication; increase in cell volume; loss of glycophorin A, an erythroid membrane protein; and synthesis of megakaryoblast proteins, such as glycoprotein IIIa, platelet peroxidase, thromboxane A₂ receptors, the A and the B chains (c-sis) of PDGF, TGF-1, urokinase-plasminogen activator and its specific inhibitor, type 1 plasminogen activator inhibitor.

Differentiation of a number of hematopoietic cell types appears to require inhibition of cellular proliferation. High level expression of the c-myc proto-oncogene appears to favor cellular proliferation over differentiation (reviewed in Ref. 6). This conclusion is based upon three observations: (i) c-myc expression declines an order of magnitude during the early stages of differentiation (7-9); (ii) continuous expression of a c-myc transgene linked to a strong promoter blocks induced differentiation (10-15); and (iii) oligonucleotides complementary to c-myc mRNA inhibit proliferation and induce differentiation (16). Thus, changes in the levels and timing of c-myc expression are essential to permit hematopoiesis, and it is thus important to understand at the molecular level how the cell effects these changes. Transcription of the c-myc gene appears to be constitutive during differentiation of K562 cells to megakaryoblasts (17). However, steady-state levels of c-myc mRNA decline at least 10-fold during the course of differentiation of murine erythroid leukemia cells, human monoblastic cells, and K562 cells (10-15, 17). This suggests that mRNA destabilization may exert a role in c-myc down-regulation during hematopoiesis. Here, I have examined the decay of c-myc mRNA during megakaryoblastic differentiation of K562 cells, utilizing both whole cells and in vitro mRNA decay assays. TPA induces a 20-fold decline in c-myc mRNA levels within 2 h. The decline likely results in part from a 4-fold acceleration in the decay rate of c-myc mRNA beginning 30-60 min after TPA addition. An in vitro mRNA decay system reconstitutes the destabilization effect and requires two cellular fractions: polysomes from TPA-treated cells and the 130,000 × g postribosomal supernatant (S130) from either untreated or TPA-treated cells. Therefore, TPA appears to activate or induce a polysome-associated component that, in concert with the S130 factor(s), acts to promote the rapid decline in c-myc mRNA levels in differentiating megakaryoblasts.

In proliferating cells, c-myc mRNA rapidly decays by a sequential pathway involving rapid removal of the poly(A) tract to generate a deadenylated or oligoadenylated form; this is followed by degradation of the mRNA body generating 3'-terminal decay intermediates. Its decay then continues in a 3'5' direction (18). c-myc mRNA decays via this pathway in vitro as well (19, 20). However, in differentiating cells and in extracts of these cells, c-myc mRNA appears to decay, at least in part, by an additional mechanism that may not require prior conversion of polyadenylated molecules to a deadenylated form.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Restriction enzymes, RNasin, and plasmid pGEM-7Zf(+) were obtained from Promega Corp. (Madison, WI). Plasmid pSM-1 was obtained from the American Type Culture Collection (Rockville, MD). TPA and RNase T1 were obtained from Sigma Chemical Co. (St. Louis, MO). RNase H and oligo(dT)-cellulose type 7 were from Amersham Pharmacia Biotech (Piscataway, NJ). Creatine phosphate, creatine phosphokinase, actinomycin D, and yeast tRNA were from Calbiochem (La Jolla, CA). [-³²P]UTP and [-³²P]GTP were from ICN Biomedicals (Irvine, CA). Oligodeoxynuclotide synthesis was performed by Operon Technologies (Alameda, CA). All other reagents were molecular biology grade.

Plasmid Constructions and Radiolabeling of Probes-- A radiolabeled probe for detection of human -globin mRNA by nuclease S1 mapping was prepared by 3'-end labeling of plasmid pDCY2 digested with EcoRI as described (19). The remaining probes, described below, were prepared by in vitro transcription of linearized plasmid templates using SP6 RNA polymerase and [-³²P]UTP (>800 Ci/mmol), unless otherwise noted, as described (19).

The same c-myc probe was used for both RNase protection assays and for RNA blot analyses. It was prepared by in vitro transcription of SspI-digested plasmid pSP65myc(CLARI) (19). For PDGF-B (c-sis) mRNA, the 2.8-kb HindIII-SacI fragment of plasmid pSM-1 (21) was subcloned into the HindIII-SacI site of plasmid pGEM-7Zf(+) to generate plasmid pGEM-huSIS-5'. The PDGF-B probe was prepared by in vitro transcription of BamHI-digested plasmid pGEM-huSIS-5'. The probe protects a 277-nt region spanning nt 1949-2225. The -actin probe was prepared by in vitro transcription of EcoRI-digested plasmid pGW02. This probe protects a 189-nt region spanning nt 1261-1449. For TGF-1, clone 589749 (GenBank^TM accession number AA148092) from the IMAGE consortium human cDNA library (Integrated Molecular Analysis of Genomes and their Expression (22)) was obtained from Genome Systems, Inc. (St. Louis, MO). A DNA fragment spanning nt 1607-1861 of the TGF-1 cDNA sequence (23) was obtained by polymerase chain reaction using a 5'-primer incorporating a HindIII site and a 3'-primer incorporating an EcoRI site. The fragment was subcloned into the HindIII-EcoRI sites of pGEM-7Zf(+) to generate plasmid pTGF (nt 1607-1861). The TGF-1 probe was prepared by in vitro transcription of HindIII-digested plasmid pTGF (nt 1607-1861) using T7 RNA polymerase. A 245-nt, ³²P-labeled, sense-strand RNA containing the c-myc coding region determinant (CRD (24)) was prepared by transcription of EcoRI-digested plasmid pGEM-myc(XhoII/Nsi) (gift of J. Ross) using [-³²P]GTP. All probes were labeled to a specific activity of at least 20,000 cpm/fmol.

Actinomycin D Treatment of Cells, Preparation of RNA, and RNA Analyses-- TPA was dissolved in 100% ethanol, and its concentration was determined by absorbance at 333 nm, using  = 5400. Exponentially dividing K562 cells, a human cell line established from a patient with chronic myeloid leukemia in blast crisis (3, 4), were cultured for 1 h either without or with TPA (20 ng/ml final concentration). Cells were then cultured with 5 µg/ml actinomycin D for various lengths of time at 37 °C to inhibit transcription. For each time point, cells were harvested and total RNA was prepared by lysis of cells, phenol extraction of proteins, and pelleting of RNA through a pad of CsCl as described (25). RNA concentrations were determined spectrophotometrically by absorption at 260 nm. In some experiments 10-µg aliquots of RNA from each time point were separated into poly(A⁺) and poly(A) fractions by batch adsorption and elution with oligo(dT)-cellulose as described (18). -Globin mRNA was detected by S1 nuclease mapping as described (18). c-myc, PDGF-B, TGF-1, and -actin mRNAs were detected by RNase P1+T1 protection assays as described (19). Bands were quantified by capturing the gel images from x-ray film using a Kodak DC120 digital camera and then analyzing the images using 1D Image Analysis Software (version 3.0; Eastman Kodak, New Haven, CT).

RNase H Mapping Analysis of Poly(A) Tract Lengths-- 10 µg of each RNA sample was subjected to oligonucleotide-directed RNase H cleavage exactly as described (18) using an antisense c-myc oligodeoxynucleotide (5'-CAAGTTCATAGGTGATTGCTG-3'), which anneals approximately 400 nt upstream of poly(A) site 2 (19). RNA samples were then fractionated in a denaturing agarose gel and blotted to a membrane. The 3'-end of c-myc mRNA was detected by incubating the membrane with a ³²P-labeled, 3'-end-specific probe (see above), washing the membrane, and exposing it to x-ray film as described (19). This RNase H mapping procedure permits a higher resolution analysis of poly(A) tract lengths than traditional Northern blotting (26, 27).

Preparation of Cellular Extracts-- Polysomes and the 130,000 × g postribosomal supernatant (S130) were prepared from K562 cells using Buffer A (10 mM Tris-HCl (pH 7.6), 1 mM magnesium acetate, 1.5 mM potassium acetate, 2 mM dithiothreitol, 1 µg each of leupeptin and pepstatin A per ml, 0.1 mM phenylmethylsulfonyl fluoride) as described previously (19).

In Vitro mRNA Decay Reactions-- In vitro mRNA decay reactions were incubated at 37 °C (unless otherwise noted) for various times in 10-µl volumes containing 0.3 A₂₆₀ units of polysomes and 28 µg of S130 protein (or 28 µg of BSA as a control). These amounts correspond to approximately 1 × 10⁶ cell equivalents of polysomes and S130. Reactions also contained 10 mM Tris-HCl (pH 7.6), 5 mM magnesium acetate, 100 mM potassium acetate, 2 mM dithiothreitol, 10 mM creatine phosphate, 0.1 unit of creatine phosphokinase, 1 mM ATP, 0.4 mM GTP, 0.1 mM spermine, and 2 units of RNasin. RNA was purified for each time point, and c-myc and -globin mRNAs were analyzed as described above.

Characterization of an S130-associated Destabilizing Activity-- To characterize the protein and nucleic acid requirements of an S130-associated activity required for TPA-induced destabilization of c-myc mRNA in vitro, S130 from TPA-treated cells was treated with either proteinase K or micrococcal nuclease, exactly as described by Brewer and Ross (28).

Gel Mobility Shift Assay-- 1 ng of ³²P-labeled RNA containing the c-myc CRD was incubated at 30 °C for 10 min in mixtures identical to in vitro mRNA decay reactions except that they also contained 10 µg of tRNA and 10% glycerol. Unbound RNA was digested by addition of 1 unit of RNase T1 and incubation at 30 °C for 10 min. To reduce nonspecific protein-RNA interactions, 50 µg of heparin was added and incubation was continued for 10 min. Protein-RNA complexes were resolved in a 6% native polyacrylamide gel as described (24, 29, 30), detected by exposure to x-ray film, and analyzed by phosphorimaging.

Western Blotting and Immunodetection-- Proteins were fractionated in 10% polyacrylamide-SDS gels and transferred to nitrocellulose in 10 mM CAPS. For CRD-BP the blot was incubated with chicken anti-CRD-BP IgY (gift of J. Ross) at 1:2000 in phosphate-buffered saline containing 0.5% milk solids and 0.05% Nonidet P-40 (31). For AUF1 the blot was incubated with rabbit anti-AUF1 serum at 1:3000 in phosphate-buffered saline containing 5% milk solids (32). Blots were then incubated with horseradish peroxidase-conjugated anti-immunoglobulin antibodies and developed by chemiluminescence (Pierce).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

TPA-induced Differentiation and Down-regulation of c-myc mRNA-- TPA treatment of K562 cells activates a genetic program that results in changing patterns of gene expression leading to megakaryoblastic differentiation. c-myc mRNA is known to decline in K562 cells after 1 day of TPA treatment (17). However, I wished to determine if there were rapid fluctuations in c-myc levels at early times after induction of differentiation. To examine potential fluctuations in c-myc expression during differentiation, exponentially dividing K562 cells were cultured in the presence of TPA. RNA was extracted from cells at various times, and the level of c-myc mRNA was measured by RNase P1+T1 protection assay employing a 620-nt radiolabeled RNA probe complementary to the 3'-terminal 210 nt of c-myc mRNA (Fig. 1). The time-zero RNA generated four protected fragments corresponding to c-myc mRNA molecules polyadenylated at four closely spaced sites. Historically, these are referred to as poly(A) site 2 (19). Quantitation of band intensities as a function of time indicated that the level of c-myc mRNA declined about 20-fold within 2 h. This effect was also reproducible, having been observed in two independent experiments and with multiple repeats of the RNase protection assay (data not shown). After 2 h, levels of c-myc mRNA then increased transiently and then decreased again over the next several days. Because K562 cells can lose their capacity for differentiation during long-term culture (33), the levels of -globin, PDGF-B, TGF-1, and -actin mRNAs were also examined to ensure that the cells have maintained their fidelity for differentiation. Both PDGF-B and TGF-1 are markers for megakaryoblastic differentiation (5). The levels of -globin mRNA, an erythroid-specific mRNA, remained relatively constant for 24 h but then declined about 80% by 72 h. This is consistent with the loss of erythroid properties. By contrast, the levels of both PDGF-B and TGF-1 mRNAs were induced by TPA. -Actin mRNA levels were maximal at 6 h of TPA treatment and then steadily declined between 6 and 72 h. This result is consistent with other reports concerning TPA-induced differentiation of K562 cells to megakaryoblasts, where a decrease in -actin expression was reported to occur as differentiation proceeded (34). Taken together, these results are consistent with TPA-induced maturation of K562 cells to megakaryoblasts.

View larger version (51K): [in this window] [in a new window]   Fig. 1.   Alterations in gene expression in differentiating K562 cells. Exponentially dividing K562 cells were treated with 20 ng/ml TPA for the indicated number of hours. RNA was purified from cells harvested at each time point. 5 µg of RNA was analyzed for levels of individual mRNAs by RNase P1+T1 protection assays (or S1 nuclease mapping for -globin mRNA) using radiolabeled probes specific for the indicated mRNAs (see "Experimental Procedures"). Protected fragments were separated in 5% polyacrylamide, 7 M urea gels and visualized by exposure to x-ray film. Bands were quantified by analysis of digitally captured video images of the gels. A bar graph of mRNA levels (percentage maximum) versus time is shown to the right of each gel panel. In some cases, 15 µg of RNA from exponentially dividing K562 cells and 15 µg of Escherichia coli tRNA were also analyzed as controls. For c-myc mRNA, pA2 indicates the protected fragments corresponding to poly(A) site 2 molecules (19).

Rapid down-regulation of c-myc mRNA levels is an essential step in the early stages of differentiation of a number of hematopoietic cell lineages (10-15). In K562 cells, the levels of c-myc mRNA decline (Fig. 1) even though transcription of the gene remains active (17). To determine if c-myc mRNA is destabilized during this early period, K562 cells were treated with TPA for 1 h and exposed to actinomycin D to inhibit transcription. Cells were harvested for purification of total RNA at various time points. Decay of c-myc mRNA was examined by RNase protection assay. The mRNA was degraded 4-fold faster in TPA-treated cells (estimated half-life 10 min) than in untreated cells (half-life 45 min) (Fig. 2A, compare lanes 10-16 with lanes 3-9; Fig. 2B; see also Fig. 6). By contrast, -globin mRNA remained stable (Fig. 2C). Thus, mRNA destabilization is selective during the early stages of differentiation, and destabilization of c-myc mRNA likely contributes to its rapid decline during TPA treatment.

View larger version (43K): [in this window] [in a new window]   Fig. 2.   Comparison of c-myc mRNA decay in dividing and differentiating K562 cells. A, exponentially dividing K562 cells were either left untreated (control), or cultured with 20 ng/ml TPA for 1 h, or cultured sequentially first with 100 µg/ml cycloheximide (chx) for 1 h and then with 20 ng/ml TPA for 1 h. Actinomycin D was added to each flask. At various times thereafter, cells were harvested and total RNA was prepared. c-myc mRNA was analyzed for each time point by an RNase P1+T1 protection assay using a 620-nt, 32P-labeled probe spanning the last 210 nt of c-myc mRNA as described under "Experimental Procedures." Protected fragments were separated in a 5% polyacrylamide/7 M urea gel and detected by autoradiography. pA2 indicates the protected fragments corresponding to poly(A) site 2 molecules (19). Lane 1 is an analysis of 15 µg of total RNA from exponentially dividing cells to demonstrate probe excess. Lane 2 contains 15 µg of E. coli tRNA as a negative control. Lanes 3-9 are RNAs from control K562 cells. Lanes 10-16 are RNAs from TPA-treated cells. Lanes 17-20 are RNAs from cells sequentially treated with cycloheximide then TPA. B, quantitation of the RNase protection assay. Bands were quantified by analysis of a digitally captured video image of the gels in A and are plotted as a percentage of c-myc mRNA remaining at each time point compared with time zero. C, analysis of -globin mRNA decay in K562 cells. 0.5 µg of the indicated RNA samples from A were assayed for -globin mRNA by S1 nuclease mapping using a 32P-labeled probe that spans the last 167 nt of -globin mRNA. Protected fragments were detected by exposure to x-ray film. Lane 1 is 1.5 µg of RNA from exponentially dividing K562 cells as a positive control. Lane 2 is 1.5 µg of E. coli tRNA as a negative control. Lanes 3-6 are RNA from control cells. Lanes 7-10 are RNA from TPA-treated cells.

Reconstitution of TPA-induced mRNA Destabilization by Cell-free Extracts-- Our long-term goal is to define the cellular components required for regulation of c-myc mRNA decay in dividing and differentiating cells. We and others have utilized cell-free systems to dissect mRNA decay (reviewed in Ref. 35; see also Ref. 36). Polysomes, with or without the S130 fraction, are incubated for various times in a buffer containing monovalent and divalent cations, ATP/GTP, an ATP-regenerating system, and RNasin (to inhibit indiscriminate degradation of all RNAs). The decay of individual mRNAs is then assessed by nuclease protection assays.

Trans-acting factors that contribute to the decay of c-myc mRNA are localized in both the polysome and S130 fractions (19, 20, 28). Thus, to identify cellular factors required to reconstitute TPA-induced destabilization of c-myc mRNA in vitro, polysome and S130 fractions from untreated (control) and TPA-treated cells were mixed in a variety of combinations and incubated for various times in decay reactions. Decay of endogenous, polysome-bound c-myc mRNA was then assessed in each case by RNase protection assays. Either control S130 or TPA S130 mixed with control polysomes accelerated c-myc mRNA decay relative to reactions supplemented with BSA (Fig. 3A, compare lanes 8-16 with lanes 3-7), consistent with earlier identification of an S130-associated destabilizing activity in dividing cells (28). However, control S130 and TPA S130 were equally effective. Likewise, either control S130 or TPA S130 mixed with TPA polysomes accelerated c-myc mRNA decay relative to reactions supplemented with BSA (Fig. 3B, compare lanes 8-16 with lanes 3-7). Again, control S130 and TPA S130 were equally effective. However, the magnitude of the destabilization effect was greatest in reactions containing polysomes from TPA-treated cells and S130 from either control cells or TPA-treated cells (compare Fig. 3B, lanes 8-16 with Fig. 3A, lanes 8-16). These data are depicted in graph form in Fig. 3C (left panel). Thus, a TPA-inducible component appeared to be associated with polysomes. This TPA-inducible, polysome-associated component(s) required the S130 fraction, however, because c-myc mRNA decay rates were comparable in polysome-containing reactions supplemented with BSA instead of the S130 (compare Fig. 3A, lanes 3-7 with Fig. 3B, lanes 3-7). Additionally, the TPA-induced destabilizing effect observed with the S130s and TPA polysomes was selective, because -globin mRNA was stable under these conditions (Fig. 3D). Taken together, the results indicate that: (i) TPA-induced destabilization of c-myc mRNA can be reconstituted in vitro; (ii) destabilization in vitro requires polysomes from TPA-treated cells and S130; and (iii) the S130 from either untreated or TPA-treated cells is equally effective. Thus, although the TPA-inducible component(s) fractionates with polysomes, it must act in concert with S130 components to effect destabilization of c-myc mRNA.

View larger version (35K): [in this window] [in a new window]   Fig. 3.   Destabilization of c-myc mRNA in vitro with extracts prepared from differentiating K562 cells. A, in vitro mRNA decay reactions with control polysomes. Standard in vitro mRNA decay reactions containing polysomes from exponentially dividing (control) K562 cells were supplemented with 28 µg of either BSA (lanes 3-7), control S130 proteins (lanes 8-12), or S130 proteins from TPA-treated cells (lanes 13-16). Reactions were incubated at 37 °C for the indicated times, and RNA was then extracted. c-myc mRNA was analyzed by the RNase P1+T1 protection assay using 5 µg of RNA. Lanes 1 and 2 are positive and negative control RNAs, respectively. B, in vitro mRNA decay reactions with TPA polysomes. Decay reactions containing polysomes from TPA-treated cells were supplemented with 28 µg of either BSA (lanes 3-7), control S130 proteins (lanes 8-12), S130 proteins from TPA-treated cells (lanes 13-16), or S130 proteins from cells sequentially treated with cycloheximide then TPA (lanes 17-21). c-myc mRNA was analyzed by RNase P1+T1 protection assays. Lanes 1 and 2 are positive and negative control RNAs, respectively. C, quantitation of the RNase protection assays. Bands were quantified by analysis of digitally captured video images of the gels in A and B and are plotted as a percentage of c-myc mRNA remaining at each time point compared with time zero. The decay rate of c-myc mRNA in reactions containing S130 depended only on the source of the polysomes; S130s from control or TPA-treated cells were interchangeable. Left panel, graphs of c-myc mRNA levels versus incubation time for reactions containing polysomes from control or TPA-treated cells plus BSA (filled circles), control polysomes plus S130 from either control or TPA-treated cells (open squares), and TPA polysomes plus S130 from either control or TPA-treated cells (filled squares). Right panel, graph of c-myc mRNA levels versus incubation time for reactions containing polysomes from TPA-treated cells and S130 from cells sequentially treated with cycloheximide and then TPA (filled diamonds). D, analysis of -globin mRNA decay in vitro. The indicated RNA samples from B were assayed for -globin mRNA by S1 nuclease mapping. Reactions contained polysomes from TPA-treated cells supplemented with either BSA (lanes 3-6), control S130 (lanes 7-10), or S130 from TPA-treated cells (lanes 11-13). Lanes 1 and 2 are positive and negative control RNA samples, respectively.

Cycloheximide Blocks TPA-induced mRNA Destabilization-- The in vitro decay experiments described above showed that the S130 from either untreated or TPA-treated cells was required for the TPA-induced destabilization effect. Prior work showed that an S130-associated destabilizing activity for c-myc mRNA could be inhibited by treatment of cells with the translational inhibitor cycloheximide (28). To determine if the S130 activity that participates in TPA-induced destabilization was also affected by cycloheximide, K562 cells were treated with 100 µg/ml cycloheximide for 2 h prior to a 1-h treatment with TPA. S130 was prepared for in vitro mRNA decay reactions. This S130 fraction was incubated in reactions containing polysomes from cells treated with TPA only and then analyzed for c-myc mRNA decay. c-myc mRNA was stabilized in these reactions compared with reactions containing S130 from cells not treated with cycloheximide (Fig. 3B, compare lanes 17-21 with lanes 8-16). The in vitro mRNA decay data for extracts of cycloheximide/TPA- and TPA-treated cells are depicted in graph form in Fig. 3C. The effect of cycloheximide was due solely to the S130 fraction, because the polysomes utilized in this experiment were prepared from cells treated with TPA only (i.e. without cycloheximide). The stabilization effect of cycloheximide occurred in vivo as well; culturing cells with cycloheximide prior to TPA treatment stabilized c-myc mRNA in whole cells (Fig. 2A, compare lanes 17-20 with lanes 10-16; see also Fig. 2B). Thus, a labile destabilizing activity that acts to promote c-myc mRNA decay in exponentially dividing cells may also be required for TPA-induced destabilization of the mRNA during differentiation. This was addressed further by examining selected biochemical properties of the S130-associated activity from TPA-treated cells.

Partial Characterization of the S130-associated Activity-- The requirement for a labile, S130-associated activity for TPA-induced destabilization of c-myc mRNA suggested that it is related to a destabilizing activity previously identified in the S130 of dividing cells (28). The S130 factor in dividing cells accelerates decay of c-myc mRNA in vitro but does not affect other mRNAs, such as - or -globin, H4 histone, or total polysome-bound poly(A⁺) mRNA. It is also sensitive to cycloheximide treatment of cells, as was shown above for the activity from TPA-treated cells. Moreover, it is inactivated by micrococcal nuclease treatment but not by proteinase K treatment, suggesting that it consists of a nucleic acid component(s) and proteinase-resistant protein(s) (28).

The S130-associated factor required for TPA-induced destabilization of c-myc mRNA possessed similar properties. Micrococcal nuclease treatment of S130 from TPA-treated cells inactivated the activity (Fig. 4, compare lane 5 with lane 3), but proteinase K did not (Fig. 4, compare lanes 8 and 9 with lane 3). Several control treatments indicated the following. (i) Inactivation of destabilizer activity required calcium, indicating that it was dependent on micrococcal nuclease (Fig. 4, compare lane 7 with lane 3). (ii) Calcium alone did not inactivate the destabilizer activity (Fig. 4, compare lane 4 with lane 3), which again supports the conclusion that inactivation was micrococcal nuclease-dependent. (iii) After micrococcal nuclease treatment, competitor RNA was added to the treated S130 prior to in vitro mRNA decay reactions. This control reaction was performed to eliminate the possibility of a masking artifact whereby micrococcal nuclease itself, or RNA-associated proteins released by nuclease treatment, might mask c-myc mRNA in decay reactions and block its degradation (see Ref. 28). Addition of tRNA after micrococcal nuclease treatment of the S130 did not restore mRNA-destabilizing activity to the S130 (Fig. 4, compare lane 6 with lane 3). This suggests that nucleolytic destruction of the S130-associated destabilizer activity, and not a masking artifact, was responsible for loss of c-myc mRNA decay activity. Taken together, these results suggest that the S130-associated activity required for destabilization of c-myc mRNA in differentiating cells may be the same as, or similar to, the activity found in dividing cells.

View larger version (40K): [in this window] [in a new window]   Fig. 4.   Characterization of the S130-associated destabilizing activity in TPA-treated K562 cells. Aliquots of S130 from TPA-treated cells were incubated at 30 °C for 30 min under the conditions indicated at the top of each lane, as described under "Experimental Procedures." The plus signs indicate reagents added together in the order shown. The arrows indicate sequential additions. In vitro mRNA decay reactions were then performed as described under "Experimental Procedures." Reactions shown in lanes 1 and 2 contained BSA, whereas the others contained S130. After a 20-min incubation at 37 °C, RNAs were analyzed by RNase P1+T1 protection assays.

Differentiation May Activate an Additional mRNA Decay Pathway(s)-- In both extracts of exponentially dividing K562 cells and in whole cells, c-myc mRNA decays via a sequential pathway involving conversion of polyadenylated molecules to poly(A)-deficient ones, which are then degraded 3'5' (18-20, 28, 35). To examine the in vitro decay pathway under conditions of TPA-induced differentiation, cell-free mRNA decay reactions were performed with polysomes and S130 prepared from TPA-treated K562 cells. However, due to the rapidity of c-myc mRNA degradation at 37 °C (see Fig. 3B), reactions were instead incubated at 20 °C to slow the decay rate and allow examination of poly(A) tract lengths. RNA samples were subjected to oligonucleotide-directed RNase H cleavage of c-myc mRNA for subsequent Northern blot analysis (i.e. RNase H mapping). This procedure permits a higher resolution analysis of poly(A) tracts than that of traditional Northern blotting. The blot was hybridized with a ³²P-labeled probe specific to the 3'-end of c-myc mRNA to visualize poly(A) tract lengths. Consistent with earlier results (18, 19), the time-zero RNA showed a broad band indicative of heterogeneous lengths of poly(A) tracts within the population of c-myc mRNA molecules at the time of cell lysis (Fig. 5A, lane 1). With increasing incubation times, the intensity of the broad band representing c-myc mRNA molecules declined, indicating degradation. However, the lengths of the poly(A) tracts within the population did not appear to decrease significantly (Fig. 5A, lanes 2-7), suggesting that degradation occurred in a deadenylation-independent fashion. This result contrasts with the well characterized observation of time-dependent shortening of poly(A) tracts in extracts of exponentially dividing cells (18-20, 28, 35, 36). Taken together, these observations suggest that c-myc mRNA is degraded via an alternate pathway in extracts prepared from differentiating cells.

View larger version (76K): [in this window] [in a new window]   Fig. 5.   Analyses of deadenylation of c-myc mRNA in differentiating K562 cells. A, analysis of deadenylation in extracts of K562 cells treated with TPA. In vitro mRNA decay reactions were performed for the indicated times at 20 °C with polysomes and S130 prepared from K562 cells treated with 20 ng/ml TPA for 1 h. RNAs were extracted and subjected to deoxyoligonucleotide-directed RNase H mapping analysis for c-myc mRNA as described under "Experimental Procedures." RNAs were fractionated in a 2% agarose/formaldehyde gel, blotted to a membrane, hybridized with a 32P-labeled probe for the c-myc 3'-UTR, and exposed to x-ray film. For reference, lane 8 contains time-zero RNA that had also been treated with oligo(dT)12-18 and RNase H to remove poly(A) tracts (19). B, analysis of deadenylation in K562 cells treated with TPA. Exponentially dividing K562 cells were treated with 20 ng/ml TPA for 1 h. Actinomycin D was added, and total RNA was isolated at various times thereafter. RNAs were analyzed for c-myc mRNA by deoxyoligonucleotide-directed RNase H mapping and blot hybridization as described for A. The nt lengths of size markers are denoted on the right.

For comparison, the decay pathway of c-myc mRNA was examined in whole cells during TPA-induced differentiation. K562 cells were treated with TPA for 1 h. At short time points after addition of actinomycin D, cells were harvested for RNA isolation. RNA samples were analyzed by RNase H mapping of c-myc poly(A) tracts (Fig. 5B). To estimate deadenylation rates, poly(A) tract lengths were measured as a function of time. Because the population of c-myc mRNA molecules contained poly(A) tracts of heterogeneous lengths, the length of the longest poly(A) tract detectable at each time point between 0 and 20 min was measured. (The signals for the 30- and 60-min time points were too faint to provide reliable measurements.) This analysis revealed a deadenylation rate of about 3 nt/min. A similar analysis of RNA samples from exponentially dividing cells indicated a deadenylation rate of about 2 nt/min (e.g. see Fig. 1 in Ref. 18). This 50% difference in deadenylation rates is not sufficient to account for the 4-fold shorter half-life of c-myc mRNA in differentiating cells versus dividing cells (10 and 45 min, respectively) as determined from the data in Fig. 2. Together, these results suggest that, during megakaryoblastic differentiation, c-myc mRNA molecules are degraded in part through an additional, deadenylation-independent pathway.

To explore this possibility further, the decay rates of c-myc mRNA in both the poly(A⁺) and poly(A) RNA fractions were compared using RNA samples from dividing and differentiating cells treated with actinomycin D for various times. The rationale for this approach is based upon the following three observations. (i) Dividing cells contain both a poly(A⁺) and a poly(A) population of c-myc mRNA molecules (18, 37). (ii) Kinniburgh and colleagues (37) demonstrated that poly(A) c-myc mRNA appears to decay with slower kinetics compared with the rapid kinetics of poly(A⁺) c-myc mRNA decay in exponentially dividing promyelocytes (HL-60 cells). They interpreted this result in terms of a precursor-product relationship whereby the poly(A⁺) precursor mRNA decayed to a poly(A) product, which then subsequently decayed (i.e. a sequential decay pathway). Thus, the apparent difference in kinetics was due to the rapidly decaying pool of poly(A⁺) c-myc mRNA replenishing the pool of poly(A) c-myc mRNA. The pool of poly(A) mRNA subsequently decreased in abundance by decay once the poly(A⁺) precursor pool was nearly depleted. (iii) By contrast, in differentiating HL-60 cells, Kinniburgh and colleagues (38) found that both poly(A⁺) and poly(A) forms of c-myc mRNA decay with similar kinetics. They interpreted this result to mean that polyadenylated c-myc mRNA decayed directly without its prior conversion to a deadenylated form in differentiating HL-60 cells. Thus, comparisons of mRNA decay rates in poly(A) and poly(A⁺) fractions of dividing and differentiating K562 cells should permit determination of the decay pathways operative in each case.

For analysis of K562 cells, RNAs from dividing and differentiating cells, treated with actinomycin D for various times, were separated into poly(A⁺) and poly(A) fractions by oligo(dT)-cellulose chromatography. c-myc mRNA was analyzed in each case by RNase protection assays. Poly(A⁺) c-myc mRNA decayed with first order kinetics with a half-life of about 45 min (Fig. 6A, lanes 1-7 and right panel). By contrast, poly(A) c-myc mRNA levels increased transiently between 0 and 30 min and then declined with first order kinetics (Fig. 6A, lanes 8-14 and right panel). These time-dependent changes in the levels of the poly(A⁺) and poly(A) forms would be expected for a sequential, two-step process in which the second step (degradation of deadenylated molecules) occurred at a rate slower than the first step (poly(A) shortening). Thus, the data in Fig. 6A are consistent with the previously reported sequential decay pathway involving conversion of the polyadenylated molecules to a poly(A)-deficient state followed by rapid degradation of the poly(A)-deficient molecules (18-20, 37). However, the kinetic profile of c-myc mRNA decay in differentiating cells differed in several ways from the kinetic profile observed in dividing cells. (i) Decay of poly(A⁺) c-myc mRNA from TPA-treated cells followed first order decay kinetics with a half-life of 12 min (Fig. 6B, upper panels). This is about 4-fold faster than the decay rate in dividing cells. (ii) Poly(A) c-myc mRNA in differentiating cells decayed with kinetics similar to those for poly(A⁺) mRNA, again with a half-life of about 12 min (Fig. 6B, lower panels). These results, taken together with the observation that deadenylation rates differ by only about 50% in dividing and differentiating cells, suggest that differentiation activates an additional decay pathway that permits direct degradation of polyadenylated mRNA molecules without their prior conversion to a poly(A)-deficient form. The in vitro mRNA decay experiments shown in Fig. 5A provide support for this additional pathway as well.

View larger version (58K): [in this window] [in a new window]   Fig. 6.   Analyses of poly(A+) and poly(A) c-myc mRNA decay in dividing and differentiating K562 cells. Actinomycin D was added to cultures of either dividing cells or cells treated with 20 ng/ml TPA for 1 h. Total RNA was isolated at the indicated time points. An aliquot of RNA from each time point was separated into poly(A+) and poly(A) fractions by batch adsorption and elution with oligo(dT)-cellulose as described under "Experimental Procedures." RNAs were analyzed for c-myc mRNA by RNase P1+T1 protection assay and visualized by exposure to x-ray film. A, analysis of poly(A+) (lanes 1-7) and poly(A) (lanes 8-14) c-myc mRNA in dividing cells. In B: Upper panel, analysis of poly(A+) c-myc mRNA in differentiating cells using the same RNA samples described in Fig. 5B. Lower panel, analysis of poly(A) c-myc mRNA in differentiating cells using the same RNA samples described in Fig. 5B. In each case bands were quantified by analysis of video-captured images of the gels. Data are plotted as a percentage of c-myc mRNA remaining versus time. The plots are presented to the right of each gel panel.

Activity of the c-myc CRD-binding Protein in Extracts-- Much work to date suggests that the coding region of c-myc mRNA, and not the 3'-UTR, controls the level of the mRNA during differentiation (12, 39-42). One region of the open reading frame implicated in regulation is the CRD, which spans nt 1705-1886 (24, 43). The 70-kDa CRD-BP is thought to bind the CRD and protect the mRNA from endonucleolytic attack. In cell-free decay experiments, addition of RNA containing the CRD accelerates decay of polysome-bound c-myc mRNA presumably by acting as a competitor for binding by CRD-BP. The competitor RNA is believed to unmask an endonucleolytic degradation site that normally is protected by CRD-BP (24, 44, 45). To test whether changes in the RNA-binding activity of CRD-BP could account for the TPA-induced destabilization of c-myc mRNA, RNA-protein band shift assays were performed. Extracts of control and TPA-treated K562 cells were incubated with ³²P-labeled RNA encoding the CRD, digested with RNase T1 to remove unbound RNA, then fractionated on a native polyacrylamide gel for visualization of the RNA-protein complex. The relative amounts of the complex differed by less than 5% between extracts of control and TPA-treated cells (Fig. 7A). As a control, the levels of CRD-BP in the polysome and S130 fractions of control and TPA-treated cells were examined by immunoblotting. CRD-BP was detected exclusively in the polysome fractions, and the levels differed less than 5% between control and TPA-treated cells (Fig. 7B, upper panel). As an additional control to verify the integrity of S130 proteins, an immunoblot analysis was performed with antibody to the RNA-binding protein AUF1. This protein is present in polysome and S130 fractions albeit at lower levels in the S130 than in the polysomes (32). The AUF1 distribution was similar to that observed previously, and intact protein was readily detectable in the S130 fractions (Fig. 7B, lower panel). Thus, it is not likely that changes in CRD-binding activity per se of CRD-BP can account for TPA-induced destabilization of c-myc mRNA. However, this result does not eliminate the possibility that CRD-BP regulates c-myc mRNA decay during TPA-induced differentiation (see "Discussion").

View larger version (26K): [in this window] [in a new window]   Fig. 7.   Comparison of CRD-BP activity in dividing and differentiating K562 cells. A, electrophoretic mobility shift assay of CRD-BP activity. Equal cell equivalents of polysomes and S130s from either control cells or cells treated with TPA for 1 h were combined, incubated with a 254 nt, 32P-labeled RNA encoding the human c-myc CRD, and then incubated with RNase T1 as described under "Experimental Procedures." A control reaction contained RNA substrate alone without any cellular protein. Reactions were fractionated in a native 6% polyacrylamide gel and visualized by exposure to x-ray film. Lane 1, no cellular protein added to the reaction. Lane 2, combined polysomes and S130 from control cells. Lane 3, combined polysomes and S130 from TPA-treated cells. B, equal cell equivalents of the indicated cell extracts were fractionated by SDS-polyacrylamide gel electrophoresis and then transferred to membranes. The blots were incubated with chicken anti-human CRD-BP IgY (upper panel) or rabbit anti-serum to human AUF1 (lower panel). This was followed by incubation with horseradish peroxidase-conjugated anti-immunoglobulin antibodies and detection by chemiluminescence.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

It is now well known that the level of c-myc expression sets the balance between proliferation and differentiation (6). Down-regulation of c-myc expression appears to be necessary for differentiation and maturation of a number of hematopoietic cell types. The data presented here indicate that down-regulation of c-myc mRNA in differentiating K562 cells occurs in part through a 4-fold destabilization of the mRNA. The destabilization effect can be reconstituted in a cell-free mRNA decay system using polysomes from TPA-treated cells and S130 proteins from either control or TPA-treated cells. The S130-associated factor(s) is active regardless of whether cells are treated with TPA or not. However, it is not active in extracts of cells treated with cycloheximide prior to induction of differentiation, suggesting that continuous translation is required for its activity. In this regard, the S130-associated activity described here appears similar to the cycloheximide-sensitive, c-myc mRNA destabilizer previously identified in the S130 of exponentially dividing K562 cells (28). The observation that the aforementioned destabilizer from dividing cells and the S130-associated factor required for TPA-induced destabilization are both sensitive to micrococcal nuclease treatment (Ref. 28 and Fig. 4) suggests that the activities require a nucleic acid component and are likely related. In any event, future work will be required to purify and fully characterize the S130-associated factor(s).

The S130-associated factor apparently exerts its effect in concert with a polysome-associated component(s) that is somehow affected by TPA-induced differentiation. What might the polysome-associated factor be? Because the coding region of c-myc mRNA seems to regulate its differentiation-dependent down-regulation (12, 39, 41, 42), one likely candidate is the 70-kDa CRD-BP. CRD-BP binds c-myc mRNA within a 182-nt region encoding a portion of the helix-loop-helix/leucine zipper of c-Myc (24, 44, 45). When induced to dissociate from the mRNA in cell-free mRNA decay reactions, c-myc mRNA is exposed to endonucleolytic attack (24). This results in the destabilization of an already unstable mRNA. However, the RNA-binding activity of CRD-BP was not detectably altered in extracts of TPA-treated cells compared with extracts of control cells (Fig. 7). Thus, it is not likely that TPA treatment alters the RNA-binding activity per se of CRD-BP. Nonetheless, this protein could still modulate TPA-induced destabilization. For example, TPA might induce CRD binding by a protein that could displace CRD-BP, permitting targeted endonucleolytic degradation. In any event, future work will be required to identify the polysome-associated, TPA-induced factor(s).

Data presented here suggest that TPA-induced destabilization of c-myc mRNA involves, in part, a pathway that may be independent of deadenylation, both in vitro and in vivo (Figs. 5 and 6). Cell-based experiments of Swartwout and Kinniburgh (38) also suggested that differentiation of promyelocytic leukemia cells leads to activation of deadenylation-independent decay of c-myc mRNA. However, attempts to identify stable products of endonucleolytic cleavage have not been successful (data not shown). Nonetheless, there are several ribonucleolytic activities that could contribute to degradation of c-myc mRNA in a deadenylation-independent fashion in differentiating K562 cells. These include a polysome-associated endoribonuclease purified by Ross and colleagues (46) and the phosphorylation-dependent RNase activity of the GAP-SH3 binding protein, G3BP (47). Both of these RNases can utilize c-myc mRNA as a substrate (46, 47). Alternatively, destabilization could involve deadenylation-independent decapping and 5'3' degradation of c-myc mRNA via an Xrn1-like activity (48). Such a mechanism is responsible for nonsense-mediated mRNA decay in the yeast Saccharomyces cerevisiae (reviewed in Refs. 49-51) and possibly in mammalian cells as well (52).

In summary, c-myc mRNA is destabilized during differentiation of K562 cells to megakaryoblasts. A cell-free mRNA decay system reconstitutes this effect whereby the TPA-inducible component(s) fractionate(s) with polysomes, but it requires one or more constitutive, S130-associated factors acting in concert. Differentiation also may activate a decay pathway that does not involve deadenylation prior to degradation of the body of the mRNA; this alternate pathway appears to be operative in vitro as well. Future studies will be required to elucidate the details of the TPA-induced mRNA decay pathway and to identify the relevant trans-acting factors. The observation that destabilization of c-myc mRNA is reconstituted in vitro will aid both of these endeavors.

	ACKNOWLEDGEMENT

I thank Dr. Jeff Ross for plasmids and antibody to CRD-BP.

	FOOTNOTES

^* This work was supported by Grant CA52443 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Molecular Genetics and Microbiology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854. Tel.: 732-235-3473; Fax: 732-235-5223; E-mail: brewerga@umdnj.edu.

Published, JBC Papers in Press, August 7, 2000, DOI 10.1074/jbc.M006145200

	ABBREVIATIONS

The abbreviations used are: TPA, 12-O-tetradecanoylphorbol-13-acetate; BSA, bovine serum albumin; TGF-1, transforming growth factor-1; CRD, coding region determinant; BP, binding protein; nt, nucleotide(s); UTR, untranslated region(s); PDGF, platelet-derived growth factor; CAPS, 3-(cyclohexylamino)propanesulfonic acid.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. Sparanese and C. H. Lee CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease Nucleic Acids Res., February 28, 2007; 35(4): 1209 - 1221. [Abstract] [Full Text] [PDF]

				B. Liao, M. Patel, Y. Hu, S. Charles, D. J. Herrick, and G. Brewer Targeted Knockdown of the RNA-binding Protein CRD-BP Promotes Cell Proliferation via an Insulin-like Growth Factor II-dependent Pathway in Human K562 Leukemia Cells J. Biol. Chem., November 19, 2004; 279(47): 48716 - 48724. [Abstract] [Full Text] [PDF]

				H. Tourriere, I.-e. Gallouzi, K. Chebli, J. P. Capony, J. Mouaikel, P. van der Geer, and J. Tazi RasGAP-Associated Endoribonuclease G3BP: Selective RNA Degradation and Phosphorylation-Dependent Localization Mol. Cell. Biol., November 15, 2001; 21(22): 7747 - 7760. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF)